Europe Pemetrexed Market Size & Outlook, 2025-2033


Europe Pemetrexed Market Insights

  • As per Reed Intelligence insights, Europe’s Pemetrexed Market was valued at USD 655.67 Million in 2024 and is anticipated to expand to USD 772.03 Million by 2033.
  • From 2026 to 2033, the market is anticipated to expand at a CAGR of 1.84%.
  • Within By Application, Malignant Pleural Mesothelioma accounted for the largest market size in 2024.
  • During the forecast period, Non-Squamous NSCLC is anticipated to remain the highest-growth segment within the By Application category.

Other Key Findings


  • Europe represented 28.02% of the global Pemetrexed Market size in 2024.
  • By 2033, United States is estimated to hold the largest position in the global market in terms of size.
  • Nordic is estimated to remain the fastest-growing market in Europe, advancing to USD 39.9 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 655.67 Million
Market Size In 2033 USD 772.03 Million
Largest segment Malignant Pleural Mesothelioma
Units Revenue in USD Million
CAGR 1.84% (2025-2033)
Segmnetation Covered
Europe
  1. Germany
  2. United Kingdom
  3. France
  4. Italy
  5. Spain
  6. Russia
  7. Nordic
  8. Benelux
By Application
  1. Malignant Pleural Mesothelioma
  2. Non-Squamous NSCLC
By End-User
  1. Hospitals
  2. Oncology Centers
  3. Online Pharmacies
  4. Offline Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends